Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H Silverstone

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Journal of Psychosomatic Research|August 1, 1996
Concise assessment for depression (CAD): a brief screening approach to depression in the medically illP H Silverstone
Acta Psychiatrica Scandinavica|April 1, 1991
Is anhedonia a good measure of depression?P H Silverstone
The Journal of Clinical Psychiatry|August 8, 2001
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorderP H Silverstone, E Salinas
The Journal of Clinical Psychiatry|March 13, 1999
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study GroupP H Silverstone, A Ravindran
Journal of Psychiatry & Neuroscience : JPN|June 23, 2000
Diltiazem as augmentation therapy in patients with treatment-resistant bipolar disorder: a retrospective studyP H Silverstone, L Birkett
Biological Psychiatry|September 1, 1994
The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteersP H Silverstone, P J Cowen
International Clinical Psychopharmacology|March 1, 1997
Diltiazem, a calcium antagonist, partly attenuates the effects of dextroamphetamine in healthy volunteersJ E Fabian, P H Silverstone
Drugs|January 1, 1997
The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applicationsA J Greenshaw, P H Silverstone
International Clinical Psychopharmacology|November 1, 2002
Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxineP H Silverstone, R Entsuah, D Hackett
Psychiatry Research|August 15, 1998
Lithium does not attenuate the effects of D-amphetamine in healthy volunteersP H Silverstone, A Pukhovsky, S Rotzinger
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Journal of Psychosomatic Research|August 1, 1996
Concise assessment for depression (CAD): a brief screening approach to depression in the medically illP H Silverstone
Acta Psychiatrica Scandinavica|April 1, 1991
Is anhedonia a good measure of depression?P H Silverstone
The Journal of Clinical Psychiatry|August 8, 2001
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorderP H Silverstone, E Salinas
The Journal of Clinical Psychiatry|March 13, 1999
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study GroupP H Silverstone, A Ravindran
Journal of Psychiatry & Neuroscience : JPN|June 23, 2000
Diltiazem as augmentation therapy in patients with treatment-resistant bipolar disorder: a retrospective studyP H Silverstone, L Birkett
Biological Psychiatry|September 1, 1994
The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteersP H Silverstone, P J Cowen
International Clinical Psychopharmacology|March 1, 1997
Diltiazem, a calcium antagonist, partly attenuates the effects of dextroamphetamine in healthy volunteersJ E Fabian, P H Silverstone
Drugs|January 1, 1997
The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applicationsA J Greenshaw, P H Silverstone
International Clinical Psychopharmacology|November 1, 2002
Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxineP H Silverstone, R Entsuah, D Hackett
Psychiatry Research|August 15, 1998
Lithium does not attenuate the effects of D-amphetamine in healthy volunteersP H Silverstone, A Pukhovsky, S Rotzinger
Pageof 5